

AMENDMENTS IN THE CLAIMS

Please amend claims 6, 13, 16 and 18 to read as follows:

1 1. (Original) A method for controlling chronic inflammation in an individual, comprising:
2 administering to said individual an effective dosage of a pharmaceutical composition selected
3 from the group consisting of YG-Product, YGG-Product, Purified Leukocyte Dialysate
4 Subfraction, and a combination thereof.

1 2. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by
2 at least one of elevated C-Reactive Protein and elevated serum fibrinogen.

1 3. (Original) The method of claim 1, wherein the chronic inflammation is evidenced by
2 at least one of elevated platelet count and elevated platelet activity due to the chronic
3 inflammation.

1 4. (Original) The method of claim 1, wherein the individual has at least one condition
2 selected from the group consisting of hypertension, hypercholesterolemia, hypertriglyceridemia,
3 and obesity.

1 5. (Original) The method of claim 1, wherein the individual has at least one component
2 of the Metabolic Syndrome.

1 6. (Currently Amended) The method of claim 5, wherein the component of the Metabolic
2 syndrome is selected from the group consisting of obesity, insulin resistance, hypertension,
3 dyslipidemia, [[,]] impaired glucose tolerance, [[,]] accompanied by increased acute phase
4 proteins including C-Reactive Protein and fibrinogen.

1 7. (Original) The method of claim 1, wherein said individual has diabetes mellitus,
2 coronary artery disease or cancer.

1 8. (Original) A method for controlling elevated blood glucose level in an individual with
2 inflammation-related metabolic disturbances, comprising: administering to said individual an
3 effective dosage of a composition selected from the group consisting of YG-Product, YGG-
4 Product, Purified Leukocyte Dialysate Subfraction, or a combination thereof.

1 9. (Original) The method of claim 8, wherein the individual has at least one component
2 of the Metabolic Syndrome.

1 10. (Original) A method for preventing chronic inflammation due to the presence of or
2 potential exposure to a pathogen, environmental particulates, or environmental toxins, said
3 method comprising: administering to said individual an effective dosage of a pharmaceutical
4 composition selected from the group consisting of YG-Product, YGG-Product, Purified
5 Leukocyte Dialysate Subfraction, and a combination thereof.

1 11. (Original) A method for mitigating a symptom in a patient, said symptom
2 characteristic of chronic inflammation, said patient presenting said symptom, said method
3 comprising administering to the patient a pharmaceutical preparation containing an effective
4 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
5 combination thereof.

1 12. (Original) The method of claim 11, wherein said patient has at least one component
2 of the Metabolic Syndrome.

1 13. (Currently Amended) The method of claim 12, wherein said symptom is at least one
2 selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,
3 abdominal obesity, insulin resistance with or without glucose ~~intolerance~~ intolerance, a
4 proinflammatory state, and a prothrombotic state.

1 14. (Original) A method for mitigating a symptom in a patient, said symptom
2 characteristic of an inflammation-related metabolic disturbance, said patient presenting said
3 symptom, said method comprising administering to the patient a pharmaceutical preparation
4 containing an effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte
5 Dialysate Subfraction, or a combination thereof.

1 15. (Original) The method of claim 14, wherein said patient has at least one component
2 of the Metabolic Syndrome.

1 16. (Currently Amended) The method of claim 15, wherein said component is at least
2 one selected from the group consisting of elevated blood pressure, atherogenic dyslipidemia,
3 abdominal obesity, insulin resistance with or without glucose ~~intolerance~~ intolerance, a
4 proinflammatory state, and a prothrombotic state.

1 17. (Original) A method for deferring the progression of a patient from the Metabolic
2 Syndrome including Hypertension, to Diabetes Mellitus, Coronary Heart Disease, or Cancer,
3 said method comprising administering to the patient a pharmaceutical preparation containing an
4 effective dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate
5 Subfraction, or a combination thereof.

1 18. (Currently Amended) A method for preventing or mitigating development of
2 inflammation-related sequelae of exposure of a person to liquids or vapors containing organic
3 solvents or hydrocarbon fuels, or to environmental toxins capable of provoking chronic
4 inflammation, said method comprising:

5 (a) administering to the person a pharmaceutical preparation containing an effective
6 dosage amount of YG-Product, YGG-Product, Purified Leukocyte Dialysate Subfraction, or a
7 combination thereof;

8 (b) monitoring the person for immune function response, inflammation, and blood
9 ~~glucose~~ glucose level; and

10 (c) continuing to administer to the patient said pharmaceutical preparation until the
11 person shows a normal immune function response and normal measures of inflammatory
12 parameters.